<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594448</url>
  </required_header>
  <id_info>
    <org_study_id>3C-18-2</org_study_id>
    <secondary_id>NCI-2018-01169</secondary_id>
    <secondary_id>3C-18-2</secondary_id>
    <secondary_id>P30CA014089</secondary_id>
    <nct_id>NCT03594448</nct_id>
  </id_info>
  <brief_title>Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients</brief_title>
  <official_title>Detection of Microsatellite Instability (MSI) in Circulating Tumor DNA of Patients With Stage IV Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot trial studies how well serial liquid biopsies work in detecting microsatellite&#xD;
      instability in participants with stage IV colorectal cancer. Serial liquid biopsies may help&#xD;
      doctors learn better methods to track cancer in the bloodstream and how to use these to&#xD;
      improve cancer treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To test the hypothesis that there is high level of concordance between the electrophoretic&#xD;
      mobility profile of microsatellite biomarkers in circulating cell-free deoxyribonucleic acid&#xD;
      (ccfDNA) versus in primary tumor tissues in patients with colorectal carcinomas displaying&#xD;
      microsatellite instability.&#xD;
&#xD;
      II. To test the hypothesis that changes in the electrophoretic mobility profile of&#xD;
      microsatellite biomarkers in liquid biopsies from patients with colorectal carcinoma&#xD;
      correlate with therapeutic responsiveness measured based on Response Evaluation Criteria in&#xD;
      Solid Tumors (RECIST) criteria.&#xD;
&#xD;
      III. To determine whether microsatellite alleles generated as a result of microsatellite&#xD;
      instability detectable in liquid biopsy specimens from patients with colorectal carcinoma&#xD;
      represent the entire cancer cell population or only a subset of cancer cells differentially&#xD;
      affected by genomic instability.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants undergo collection of blood samples to evaluate microsatellite instability via&#xD;
      serial liquid biopsies at baseline, then every 6 weeks and at progression or 9 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Anticipated">September 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 5, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between presence of MSI present in circulating tumor DNA versus in primary tumor specimens</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>MSI testing distinguishes between tumors into one of 3 phenotypic categories: MSI-High (MSI-H) is reported when &gt; 30% of biomarkers show instability; Microsatellite stable (MSS) is reported in the absence of instability. The third category, MSI-Low (MSI-L) is diagnostically equivalent to MSS, and is reported when MSI is present in &lt; 30% of biomarkers. MSI status will be determined by polymerase chain reaction (PCR) using commercial kits provided by Promega.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Microsatellite Instability</condition>
  <condition>Colorectal Cancer Stage IV</condition>
  <arm_group>
    <arm_group_label>Ancillary-correlative (Specimen collection)</arm_group_label>
    <description>Participants undergo collection of blood samples in addition to the usual amount collected when they come in for their regular cancer treatments or doctor?s appointment every 6-8 weeks until disease progression or stopping at 9 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Specimen Collection</intervention_name>
    <description>Undergo collection of blood samples</description>
    <arm_group_label>Ancillary-correlative (Specimen collection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Serial Liquid Biopsy</intervention_name>
    <description>Undergo serial liquid biopsy</description>
    <arm_group_label>Ancillary-correlative (Specimen collection)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients newly diagnosed with stage IV colorectal cancer and with defined microsatellite&#xD;
        instability status before initiation of systemic immunotherapy will be recruited.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients newly diagnosed with stage IV colorectal cancer and with defined&#xD;
             microsatellite instability status before initiation of systemic immunotherapy.&#xD;
&#xD;
          -  Trackable cancer-driver mutation in the primary tumor documented before initiation of&#xD;
             chemotherapy.&#xD;
&#xD;
          -  Zubrod performance status of 0 or 1.&#xD;
&#xD;
          -  Patients have measurable disease according to RECIST version (v)1.1.&#xD;
&#xD;
          -  Ability to understand and willing to sign a written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe anemia (hemoglobin [Hb] &lt; 8 g/dL).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Afsaneh Barzi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dana Agafitei</last_name>
    <phone>323-865-0467</phone>
    <email>Raluca.Agafitei@med.usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rabia Rehman</last_name>
    <phone>323-865-0460</phone>
    <email>Rabia.Rehman@med.usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Afsaneh Barzi</last_name>
      <phone>323-865-3829</phone>
      <email>afsaneh.barzi@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Afsaneh Barzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoag Memorial Hospital</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana L. Hanna</last_name>
      <phone>949-764-6130</phone>
      <email>Diana.Hanna@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Diana L. Hanna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USC Norris Oncology/Hematology-Newport Beach</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristy Massopust</last_name>
      <phone>949-474-5733</phone>
      <email>Kristy.Massopust@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Umair Ghani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>April 1, 2021</last_update_submitted>
  <last_update_submitted_qc>April 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Microsatellite Instability</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

